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Abstract
Background: Opportunistic screening in hospitals is widely used to effectively reduce the incidence rate of cervical
cancer in China and other developing countries. This study aimed to identify clinical risk factor algorithms that
combine gynecologic examination and molecular testing (paired box gene 1 (PAX1) or zinc finger protein 582
(ZNF582) methylation or HPV16/18) results to improve diagnostic accuracy.
Methods: The delta Cp of methylated PAX1 and ZNF582 was obtained via quantitative methylation-specific PCR in a
training set (57 CIN2− and 43 cervical intraepithelial neoplasia ≥grade 3 (CIN3+) women), and the individual and
combination gene sensitivities and specificities were determined. The detection accuracy of three algorithms
combining gynecologic findings and genetic test results was then compared in a randomized case-control study
comprising 449 women referred for colposcopic examination by gynecologists in the outpatient department of
Xiangya Hospital between November 2011 and March 2013.
Results: Significant association was observed between CIN3+ and methylated PAX1 or ZNF582 in combination with
HPV16/18 (OR:15.52, 95 % CI:7.73–31.18). The sensitivities and specificities of methylated PAX1 or ZNF582 combined
with HPV16/18 for CIN3+ women were 89.2 and 76.0 %, or 85.4 and 80.1 %, respectively. Of the three algorithms
applied to cohort data and validated in the study, two indicated 100 % sensitivity in detecting cervical cancer and a
low rate of referrals for colposcopy.
Conclusions: These algorithms might contribute to precise and objective cervical cancer diagnostics in the
outpatient departments of hospitals in countries with high mortality and low screening rates or areas with uneven
resource distribution.
Keywords: Biomarkers, Algorithm, DNA methylation, HPV16/18, Cervical cancer, ZNF582, PAX1
Background
Cervical cancer is the fourth most common cancer that
affects women worldwide. The use of the cytological
test developed by George Papanicolaou (the Pap smear)
in cervical cancer screening programs has led to a re-
duction in the incidence of cervical cancer in developed
countries [1, 2]. However, most cases of cervical cancer
are still associated with absent or deficient screening
[3–6]. In China, cervical cancer remains the second-
leading cause of death from cancer among females aged
15 to 44 years, and nearly 58,000 new cases and 20,000
deaths were documented in 2005 alone. In certain
developed cities such as Beijing and Shanghai, the inci-
dence of cervical cancer has dropped significantly
because of the wide promotion of cervical cancer preven-
tion and opportunistic screening in hospitals. Despite
these advances, prevention awareness of cervical cancer is
still inadequate in most areas of China because of its large
population size [7, 8].
Oncogenic high-risk human papillomavirus (hrHPV)
DNA testing is currently an appealing method for the
molecular diagnosis of cervical cancer, as HPV plays an
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essential role in cervical carcinogenesis [9–12]. In
China, the application of HPV testing has increased
dramatically because of its consistency and reproduci-
bility. Thus, HPV testing has increased to the level of
an “HPV-heavy-burden of testing” in certain regions,
with the prevalence varying significantly among differ-
ent ages and regions [13]. Consequently, progressively
more HPV-positive patients are in need of cytological
or colposcopic examination in hospitals, which in turn
highlights the deficiencies of the examination proced-
ure and the overloading of the performing physicians
[14]. HPV-positive assay results might also cause an ad-
verse psychosocial impact on patients. P16/Ki67 dual
staining is used as a tool for CIN2 triage; however,
Wentzensen et al. reported that P16/Ki67 dual staining
yielded a 78.9 % positive rate for CIN2 and an 86.9 %
positive rate for CIN3/CIS/cancer but also exhibited a
41.1 % positive rate for the CIN2− group [15]. There-
fore, a more accurate method is required to reduce the
high false-positive rate of hrHPV testing and to main-
tain the consistency and reproducibility of methods
used in the outpatient departments of hospitals in
China or other high-population countries.
One such screening possibility arises from the field
of epigenetics [16]. Numerous investigations have re-
ported that the gene-specific hypermethylation that
occurs in the pre-invasive and invasive phases of cer-
vical cancer might serve as a promising biomarker for
early diagnosis [17, 18]. Several studies examining
paired boxed gene 1 (PAX1) and zinc finger protein
582 (ZNF582) have reported their potential utilization
as highly sensitive biomarkers for detection of cervical
intraepithelial neoplasia at grade 3 or higher (CIN3+)
[19–26]. The PAX1 gene was found to be involved in
the regulation of cell differentiation in head and neck
cancer, and the ZNF582 gene is a protein-coding gene
involved in gene expression [27, 28].
The aim of this study was to develop and verify ef-
fective clinical risk factor algorithms to increase the ac-
curacy of diagnosis for cervical cancer based on
existing validated candidate molecular tests and the
highly weighted factor of clinical examination informa-
tion from the subjects. Standardized quantitative
methylation-specific PCR tests of methylated PAX1
gene (PAX1m) and methylated ZNF582 gene (ZNF582m)
were performed on a full spectrum of cervical scrap-
ings, with cutoff values selected from the training set,
to determine the sensitivities and specificities for CIN3
+ detection in the validation set. The gynecology exam-
ination results were also considered as a prominent risk
factor in the algorithms for cervical cancer prediction.
We propose that these algorithms would be useful in
the outpatient departments of hospitals in China or
other high-population countries.
Case presentation
Patient recruitment and study design
In accordance with the Declaration of Helsinki, all pa-
tients provided informed consent for their participation
in the clinical study, whose protocol was approved by
the Institutional Review Board of the Department of
Clinical Pharmacology at Xiangya Hospital, Central South
University, China. The clinical trial was registered in the
Chinese Clinical Trial Registry (ChiCTR-DOD-14005446).
Study inclusion criteria included females who were sexu-
ally active, not pregnant, had an intact uterus, and had no
history of treatment for cervical intraepithelial neoplasia
(CIN) or cervical cancer. Patients with a history of cancer
related to the reproductive tract or therapy for cervical le-
sions or HPV vaccinations, in addition to those who had a
current pregnancy, were excluded.
Female patients who had abnormal Pap smears, cer-
vical inflammation, cervical erosion, or bleeding syn-
drome, or those who were suspected to have cervical
cancer and were referred for colposcopic examination
by the gynecologist in the outpatient department of the
hospital, were included in this study. Patients were
invited to the colposcopic examination room of the
Department of Obstetrics and Gynecology to partici-
pate in a blinded study where testers were not provided
clinical data. After patients signed an informed consent
form, a standardized personal interview was given by
experienced assistants, a case report form was filled,
and every patient received a colposcopic examination
and biopsy. The case report form included the inclusion
and exclusion criteria, basic personal information, his-
toric lifestyle and sickness records, histories of gyneco-
logic examinations and findings, cytological results, and
pathological results. The cytology results were classified
according to the 2001 Bethesda System (TBS 2001)
[29]. Colposcopy-directed biopsies were performed to
provide histological results according to standard pro-
cedures in China. Biopsy specimens were histologically
classified as normal, CIN1, CIN2, CIN3, cervical carcin-
oma in situ (CIS), squamous cell carcinoma (SCC), or
adenocarcinoma (AC), according to the international
criteria. The final diagnosis was based on the results of
tissue-proven pathology. To ensure the quality of the
diagnosis, two expert cytologists and two pathologists
independently reviewed the cytology and histology
slides, respectively. Standard guidelines for the manage-
ment and treatment of cervical neoplasia were followed
in all subjects [30]. All patient recruitment and clinical
information collection processes were periodically
monitored, and good clinical practice (GCP) guidelines
were followed.
In the intervention arm of the randomized-controlled
trial, data from the first 100 patients were used as a train-
ing set to build a prediction model that distinguished
Liou et al. Clinical Epigenetics  (2016) 8:66 Page 2 of 11
CIN3+ subjects from controls (Additional file 1: Table S1).
The validation set was composed of the subsequent 466
patients (17.6 % of the total patients in the colposcopic
room), with a mean age of 42.8 years (range, 27.5–
77.8 years), enrolled from November 2011 to March 2013.
Twelve patients were excluded based on the exclusion
criteria, and five were excluded because of poor quality
of the DNA specimens. Thus, data from 449 patients
were included in the final statistical analyses. The cri-
teria used to determine positive and negative results for
the tested methylated genes were based on the delta Cp
of the training set (described in further detail below).
Specimen collection and DNA preparation
All liquid-based cytology samples were collected using
CytoFast Solution (Hospitex Diagnostics SRL, Sesto
Fiorentino, Italy). Residual cervical cells from cytological
tests were used for HPV typing and methylation detection
tests for the two genes. All specimens collected were
assigned a number and delinked from patient clinical in-
formation until final data analysis. All molecular tests
were performed at the Institute of Clinical Pharmacology,
Hunan Key Laboratory of Pharmacogenetics, China, fol-
lowing good laboratory practice guidelines. The cells were
centrifuged and stored in phosphate-buffered saline at
−20 °C from the day of collection. Genomic DNA (gDNA)
was extracted from the collected cells using the QIAamp
DNA Mini Kit (Qiagen GmbH, Hilden, Germany). A
BioSpec-nano spectrophotometer (Shimadzu Corporation,
Tokyo, Japan) was used to quantify the amount of ex-
tracted DNA.
DNA methylation tests
Quantitative methylation-specific PCR was performed
using TaqMan-based technologies on the Lightcycler
LC480 real-time PCR system (Roche Applied Sciences,
Penzberg, Germany) with Cervi-P and Cervi-Z DNA de-
tection kits (iStat Biomedical, Taipei, Taiwan). Briefly,
500 ng of gDNA was subjected to bisulfite conversion
using EZ DNA Methylation-Gold Kits (Zymo Research,
Irvine, CA, USA). The methylation levels of the PAX1 and
ZNF582 genes were then determined using the qPCR kits
with internal controls according to the manufacturer’s rec-
ommendations. The PCR reactions consisted of an initial
incubation at 95 °C for 10 min, followed by 50 cycles of
denaturation at 95 °C for 10 s and annealing and extension
at 60 °C for 40 s. Fluorescence data were collected during
the annealing/extension step for Cp determination.
HPV DNA amplification and genotyping
The hrHPV-typing procedure was performed using a
nested multiplex PCR assay that combined degenerate
E6/E7 consensus primers and type-specific primers as
previously described [31]. hrHPV type was determined
after determining the size of the nested PCR amplifica-
tion product.
Algorithms for combining molecular tests and clinical
gynecologic examination results
To ascertain the clinical characteristics of the subjects,
items of the case report form (Table 3) including
gynecologic history were answered by patients, and the
gynecologic examination results were recorded by the
physicians for each patient in the study. The odds ratio
for each clinical characteristic was determined by uni-
variate analysis. The significantly associated factors
were then used in a multivariate logistic regression ana-
lysis to select the variables based on goodness-of-fit
analysis. Multiple regression analysis revealed that a gy-
necologic history of vaginal bleeding, grossly normal
cervix (over 90 % of the cervix had a uniform surface
without warts or masses), and a finding of cervical bleed-
ing during the gynecologic examination were associated
with CIN3+ as shown in Table 3 (adjusted P ≤ 0.05).
First, a logistic regression analysis based on molecular
tests (PAX1m and/or ZNF582m, independently or both
combined with HPV16/18) and key clinical characteris-
tics (vaginal bleeding, grossly normal cervix, and finding
of cervical bleeding) was used to discriminate between
patients with CIN3+ and CIN2− cervical lesions. The
methylated genes in the logistic regression formula for
algorithms 1 to 3 were PAX1m, ZNF582 m, and PAX1m
or ZNF582 m, respectively.
The logistic regression formula was as follows:
logistic score ¼ W1methylated gene OR½  þ W2 HPV16=18 OR½ 
þ W3 vaginal bleeding OR½  þ W4 grossly normal cervix OR½  þ
W5contact bleeding OR½ þC constant numberð Þ:
Second, the weight factor (W1–5; standardized regres-
sion coefficients) was calculated between the analytic re-
sults for the molecular tests and the key clinical
characteristics. The weight factor value is a measure of
how strongly each test influences the criterion variable
(CIN3+ lesion). Each of the scores for the individual mo-
lecular tests and key clinical characteristics was entered
into the logistic score as either “0” (negative) or “1” (posi-
tive). The results for the weight factor were calculated
using the multivariate logistic regression.
For example:
Logistic score of algorithm 2 : 2:334  ZNF582mORð Þ
þ 1:485 HPV16=18 ORð Þ þ 0:529  vaginal bleeding ORð Þ
þ −0:534  grossly normal cervix ORð Þ
þ 0:759  contact bleeding ORð Þ −2:133:
Each of the three algorithms differed in the weights
and methylated genes used. Finally, the logistic score
was transformed into a probability score. The probability
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score had a range of values from 0 to 1000, which indi-
cated the probability of CIN3+ for each algorithm [32].
The probability score was calculated as [eLogistic score]/
[1 + eLogistic score] * 1000.
Statistical analysis
The cutoff values for each methylated gene were gener-
ated from the first 100 subjects, including 43 with CIN3
+ results and 57 with CIN2− results. A cross-validated
receiver operating characteristic (ROC) curve was gener-
ated, and the area under the ROC curve (AUC) was cal-
culated for each detection method for CIN3+ lesions.
The optimal cutoff value, i.e., the delta crossing point
(ΔCp), of each methylated gene was generated using the
Youden index. The positive cutoff values for PAX1m and
ZNF582m were determined as ΔCp ≤ 9 and ΔCp ≤ 11, re-
spectively, from the first 100 subjects. SPSS software
(version 16.0, Chicago, IL, USA) was used for all statis-
tical analyses. Chi-squared and Fisher’s exact tests were
used to analyze the status of the methylated genes and
HPV genotype in different combinations. Fisher’s exact
test is considered more accurate than the chi-squared
test when the sample size is smaller than five. The sen-
sitivity, specificity, and odds ratio (OR) with a 95 %
confidence interval (CI) for lesions of grade CIN3 or
worse were calculated. All differences were considered
two-sided and statistically significant at P < 0.05. The
algorithms were based on the multivariate logistic re-
gression model.
Discussion and evaluation
Several previous studies have indicated that the analysis
of PAX1m and ZNF582m in cervical cell scrapings and
tissues holds great promise for detecting high-grade CIN
lesions and cervical cancer [19, 22]. However, these stud-
ies were conducted on selected populations such as
within an outpatient referral case control study or fol-
lowing triage using cytology or hrHPV, wherein cytology
was examined solely in LSIL patients. These study de-
signs hampered the proper comparison of molecular test
performance with cytology results, as patients with nor-
mal or partially abnormal results did not receive follow-
up exams. The strengths of the present study lie in its
incorporation of delinked random case-control study
methods incorporating all histological results, including
those of the normal group. This enabled the comparison
of the results obtained with methylation markers with
those of cytology or HPV genotyping for cervical cancer
screening.
To our knowledge, this study is the first report to val-
idate an opportunistic cervical cancer screening method
that utilizes gynecologic examination findings, gynecologic
history, and genetic biomarkers in combination to in-
crease the accuracy of diagnoses under hospital outpatient
conditions. In addition, we consider that this study also
provides the first suggestion that that the majority of cer-
vical cancer diagnoses in China or other developing coun-
tries should be obtained through opportunistic screening.
Our results demonstrated that of the two genes used in
the study, methylated ZNF582, with 76.6 % sensitivity and
86.94 % specificity for detecting cervical cancer, is a more
promising biomarker. ZNF582m has been reported to
function well in the triage of patients with equivocal
liquid-based cytology results [19, 25]. The second tested
biomarker, PAX1m, has also been reported as a useful bio-
marker for cervical cancer in the screening and triage of
cytology and for the detection cervical adenocarcinoma.
The results of this meta-analysis support the utility of
PAX1m as an auxiliary biomarker in cervical cancer
screening [33], as algorithm 1 demonstrated 89.87 % sen-
sitivity and 75.95 % specificity for PAX1m in combination
with HPV16/18 and cytology testing, which is higher than
the values obtained by testing any of these factors alone.
Both algorithms 2 and 3 showed a 100 % detection rate
in the cancer groups. We therefore recommend a new cer-
vical cancer patient management strategy consisting of
both algorithms 2 and 3 for use in opportunistic screening
in hospitals. Patients who exhibit positive test results from
algorithm 2 or 3 should then undergo a colposcopy exam-
ination or a biopsy. Upon obtaining negative results,
patients should return for follow-up examinations at
6 months or 1 year. As a cancer management strategy,
algorithm 2 might reduce the number of hrHPV-positive
patients referred for colposcopy by 38.5 %, whereas algo-
rithm 3 might reduce the referral number by 27.56 %;
however, algorithm 3 also had an 83.33 % positive rate for
the histologic CIN3 category, which is 13.89 % higher than
that obtained with algorithm 2.
In this study, the sensitivity and specificity of hrHPV
testing and Pap smear tests applied individually for de-
tecting CIN3+ were 98.1 and 46.1 %, and 69.0 and 90.7 %,
respectively. However, in China, cytology and hrHPV
diagnosis are time-consuming and impractical because of
inaccurate results. Testing is performed in many hospitals
that do not have sufficient medical resources to perform
colposcopy and additional examinations, thus impeding
proper diagnosis. Furthermore, colposcopy is invasive and
causes anxiety in many patients. In comparison, the three
proposed algorithms combine PAX1m and/or ZNF582m
with HPV16/18 testing and take into account gyneco-
logic history/examination findings to enhance accur-
acy. These algorithms could improve the positive
detection rate of CIN3+ lesions, with clinical observa-
tion and gene testing both proposed as follow-up
measures. The use of these algorithms might thus
greatly reduce the referral rate of hrHPV-positive pa-
tients and increase the accuracy of cytology in coun-
tries with limited resources for colposcopy.
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Table 1 Population and test characteristics by histologic category
Histological results Total
Cutoff Normal CIN1 CIN2 CIN3 CIS SCC/AC
Number of subjects
N (%) 218 (48.55) 30 (6.68) 43 (9.58) 72 (16.04) 15 (3.34) 71 (15.81) 449 (100)
Age (years)















Normal (%) 90 (90.91) 4 (4.04) 2 (2.02) 0 (0.00) 1 (1.01) 2 (2.02) 99 (100)
ASC-US (%) 112 (53.85) 21 (10.10) 32 (15.38) 24 (11.54) 5 (2.40) 14 (6.73) 208 (100)
LSIL (%) 1 (16.67) 2 (33.33) 0 (0.00) 3 (50.00) 0 (0.00) 0 (0.00) 6 (100)
ASC-H/AGC/HSIL+ (%) 15 (11.03) 3 (2.21) 9 (6.62) 45 (33.09) 9 (6.62) 55 (40.44) 136 (100)
Detection modality or test used
hrHPV (%) 100 (45.87) 18 (60.00) 39 (90.70) 71 (98.61) 15 (100) 69 (97.18) 312 (69.49)
HPV16/18 (%) 19 (8.72) 5 (16.67) 12 (27.91) 36 (50.00) 11 (73.33) 56 (78.87) 139 (30.96)
PAX1m (%) ΔCp ≦ 9.0 34 (15.60) 4 (13.33) 15 (34.88) 47 (65.28) 11 (73.33) 52 (73.24) 163 (36.30)









The present study has some potential limitations. For ex-
ample, the subjects who were recruited were seen following
referral for colposcopy examination and consisted of patients
who had abnormal Pap smear results, inflammation syn-
drome, cervical erosion, bleeding syndrome, or suspected
cervical cancer. In our cohort, >90 % of the patients had in-
flammation syndrome with positive hrHPV findings, which
is not representative of the general population. In addition,
many ASC-US patient samples were collected in the colpos-
copy room because most patients with obvious cervical can-
cer underwent biopsy immediately following abnormal Pap
smear test results and clinical observation in the outpatient
department. Other limitations include a small sample size
and a lack of extensive and long-term follow-up information.
Patient clinicopathological characteristics
Cohort demographic characteristics, clinical information, and
PAX1m and ZNF582m testing results are shown in Table 1.
The cytology results of the cohort indicated that 99 were
normal, 208 had atypical squamous cells of undetermined sig-
nificance (ASC-US), 6 exhibited low-grade squamous intrae-
pithelial lesion (LSIL), and 136 had atypical squamous cells for
which HSIL/atypical glandular cell of undetermined signifi-
cance/high-grade squamous intraepithelial lesion+ (ASC-H/
AGC/HSIL+) status could not be excluded. In total, colpos-
copy and biopsy revealed normal histology in 218 (48.55 %)
patients, CIN1 in 30 (6.68 %) patients, CIN2 in 43 (9.58 %) pa-
tients, CIN3 in 72 (16.04 %) patients, CIS in 15 patients
(3.34 %), and SCC/AC in 71 (15.81 %) patients. The positive
rates of PAX1 m and ZNF582 m in the CIN3+ group were 69.6
and 77.6 %, respectively.
Analytic sensitivity and specificity of the methylation
analysis combined with HPV genotyping in the
validation set
Table 2 shows the results of the sensitivity, specificity,
and accuracy for different molecular tests and their
combinations for detection of CIN3+ lesions. The AUCs
of HPV16/18, PAX1m, and ZNF582m in the validation set
were 76.4, 75.5, and 81.8 %, respectively. The sensitivity
and specificity of HPV16/18 for detecting CIN3+ lesions
were 65.19 and 87.63 %, respectively, whereas PAX1m
showed 69.6 % sensitivity (95 % CI 62.1–76.3) and 81.8 %
specificity (95 % CI 77.0–85.8), and ZNF582m exhibited
76.6 % sensitivity (95 % CI 69.4–83.0) and 86.9 % specifi-
city (95 % CI 82.6–90.3). We therefore analyzed PAX1 m
and ZNF582 m as reliable molecular tests in comparison
to Pap smear results.
In the combined parallel testing of gene methylation
with HPV genotyping, ZNF582m and PAX1m combined
with HPV16/18 results exhibited an AUC >82 % for de-
tection of CIN3+. ZNF582m combined with HPV16/18
showed the best combination of high sensitivity (85.4 %)
and high specificity (81.1 %), whereas PAX1m combined
with HPV16/18 had the highest sensitivity of 89.2 % and
a specificity of 76.0 %. The combination of both methyl-
ated genes, ZNF582m and PAX1m, exhibited 85.4 % sen-
sitivity and 77.0 % specificity.
Algorithms combining gynecologic examination findings
and genetic test results
The crude ORs and corresponding 95 % CIs for predic-
tion of CIN3+ lesions in the study cohort were calcu-
lated. Univariate analyses revealed that age, number of
pregnancies, contraceptive measures such as condom
use, gynecologic history, and certain gynecologic exam-
ination findings were significantly (P < 0.05) associated
with CIN3+, as shown in Table 3. Patients who were
over 50 years old (OR:2.97, 95 % CI:1.13–7.8) and those
from 30 to 50 years of age (OR:2.13, 95 % CI:0.68–6.69)
were found to have a higher risk of CIN3+ lesions com-
pared to patients under 30 years of age. Patients who
had given birth over three times or had a cervical mass
finding on tumor examination were still considered to
Table 2 Performance of methylated genes and HPV tests for CIN3+ detection
Tests Sensitivity (%) (95 % CI) Specificity (%) (95 % CI) AUC (%) (95 % CI) Odds ratio (95 % CI) P value
PAX1m 69.62 (62.05–76.26) 81.79 (76.95–85.80) 75.5 (70.8–80.6) 10.29 (6.55–16.16) <0.001
ZNF582m 76.58 (69.40–82.51) 86.94 (82.58–90.34) 81.8 (77.3–86.2) 21.77 (13.18–35.96) <0.001
PAP 68.99 (61.40–75.68) 90.72 (86.84–93.54) 79.9 (75.1–84.6) 21.75 (12.93–36.59) <0.001
hrHPV 98.10 (94.57–99.35) 46.05 (40.41–51.79) 72.1 (67.5–76.7) 44.10 (13.75–141.45) <0.001*
HPV-16/18 65.19 (57.48–72.18) 87.63 (83.35–90.93) 76.4 (71.4–81.4) 13.27 (8.22–21.40) <0.001
PAX1m or hrHPV 98.73 (95.50–99.65) 42.61 (37.06–48.35) 70.7 (66.0–75.3) 57.92 (14.09–238.17) <0.001*
PAX1m or HPV-16/18 89.24 (83.45–93.17) 75.95 (70.72–80.50) 82.6 (78.5–86.6) 26.19 (14.80–46.33) <0.001
PAX1m or ZNF582m 85.44 (79.10–90.10) 76.98 (71.81–81.44) 81.2 (76.9–85.5) 19.62 (11.67–32.99) <0.001
ZNF582m or hrHPV 98.73 (95.50–99.65) 45.02 (39.40–50.76) 71.9 (67.3–76.5) 63.86 (15.53–262.56) <0.001*
ZNF582m or HPV-16/18 85.44 (79.10–90.10) 81.10 (76.21–85.18) 83.3 (79.2–87.4) 25.19 (14.82–42.82) <0.001
P value determined by chi-squared test and *Fisher’s exact test; odds ratio for CIN3+
CI confidence interval, HPV human papillomavirus, hrHPV high-risk human papillomavirus, Genem methylated gene
Liou et al. Clinical Epigenetics  (2016) 8:66 Page 6 of 11
Table 3 Crude and adjust odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) for predictors of CIN3+ in cervical
cancer
Odds ratio (95 % CI)
Variable Number Crude P value Adjusted P value
Age group
<30 52 Reference Reference
30–50 319 3.93 (1.72–9.00) 0.001 2.97 (1.13–7.80) 0.027
>50 78 4.02 (1.61–10.06) 0.003 2.13 (0.68–6.69) 0.194
No. of pregnancies
0 24 Reference
1~3 232 2.68 (0.89–8.11) 0.081
>3 193 3.04 (1.00–9.25) 0.050
No. of births
0 46 Reference Reference
1~3 363 2.24 (1.05–4.79) 0.038 1.06 (0.43–2.63) 0.895
>3 40 4.54 (1.75–11.83) 0.002 1.71 (0.53–5.56) 0.370
Intrauterine device (IUD) usage
No 215 Reference
Yes 234 1.41 (0.95–2.08) 0.087
Condom usage
No 336 Reference Reference
Yes 113 0.59 (0.37–0.94) 0.027 0.78 (0.46–1.31) 0.349
Oral contraception usage
No 391 Reference
Yes 58 0.81 (0.45–1.46) 0.478
Tubal ligation
No 360 Reference
Yes 89 0.98 (0.60–1.60) 0.937
Gynecology history: cervical contact bleeding
No 329 Reference Reference
Yes 120 1.61 (1.05–2.47) 0.030 1.11 (0.68–1.80) 0.673
Gynecology history: vaginal bleeding
No 385 Reference Reference
Yes 64 3.77 (2.18–6.54) <0.001 2.95 (1.62–5.39) <0.001
Gynecology history: abnormal vaginal discharge
No 439 Reference
Yes 10 1.87 (0.53–6.56) 0.329
Gynecologic examination: grossly normal cervix
No 323 Reference Reference
Yes 126 0.40 (0.25–0.65) <0.001 0.51 (0.30–0.85) 0.011
Gynecologic examination : cervical erosion
No 196 Reference
Yes 253 1.00 (0.68–1.48) 0.995
Gynecologic examination: cervical mass
No 349 Reference Reference
Yes 100 2.01 (1.28–3.15) 0.003 1.37 (0.83–2.25) 0.220
Liou et al. Clinical Epigenetics  (2016) 8:66 Page 7 of 11




Yes 3 3.72 (0.33–41.33) 0.285
Gynecologic examination: contact bleeding
No 403 Reference Reference
Yes 46 2.95 (1.58–5.50) 0.001 1.94 (0.99–3.83) 0.055
Fig. 1 Representative values plotted versus cutoff values in cervical cancer. a–d Illustrate the sensitivity and specificity of tests (PAX1m and
algorithms) at different cutoff values for detecting CIN3+ lesions. e Bar chart showing the positivity rate for algorithms in each histologic category
when 220 was used as a cutoff value. GI gynecologic information
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be at risk for cervical cancer. In the latter analysis, patients
who had a gynecologic history of vaginal bleeding and
examination findings of contact bleeding had an approxi-
mately 3.77- to 2.95-fold higher risk of CIN3+ lesions
compared to those without these characteristics. In con-
trast, the gynecologic examination finding of a grossly
normal cervix was negatively associated with CIN3+ le-
sions; furthermore, such patients exhibited a 50 % lower
risk of CIN3+ lesions compared to those with morphology
changes.
Figure 1a shows the sensitivity and specificity of the
PAX1m gene only and the positive results determined at
the ΔCp ≤ cutoff value. Detection of the PAX1m gene
only had a limited sensitivity of approximately 80 %.
Figure 1b–d shows the range of cutoff values (probabil-
ity score) of 0 to 1000 generated for algorithm 1 to 3,
and the sensitivity and specificity of each algorithm
were plotted with the different cutoff values (probabil-
ity score). Finally, the optimal probability score was
determined to be 220 in algorithms 1 to 3 by Youden’s
J statistic.
The bar chart in Fig. 1e shows the proportion of HPV
16/18 and the detection rate for the other three algo-
rithms with each histologic category. The positive de-
tection rates for CIN3+ of the three algorithms were
higher than those for HPV16/18 alone. All algorithms
demonstrated over 86 % sensitivity and 72 % sensitivity
for the detection of CIN3+ lesions (Table 4). Algorithm
1, which showed 89.87 % sensitivity and 75.95 % speci-
ficity, was 24.7 % more sensitive and 11.7 % less specific
than HPV16/18 testing alone for detecting CIN3+
lesions, whereas algorithms 2 and 3 were 20.9 and
27.22 % more sensitive and 6.9 and 15.12 % less specific
than HPV16/18, respectively.
For cancer detection, HPV16/18 had 77.90 % sensitivity.
Algorithm 1 showed 95.77 % sensitivity, and algorithms 2
and 3 both exhibited 100 % sensitivity. Algorithm 2
showed a 23.42 % increase in sensitivity over ZNF582 test-
ing alone for the histologic cancer (CIS/SCC/AC) category
but showed only a 4.58 % increase in sensitivity for detect-
ing patients within the normal histologic category. Algo-
rithm 2 also demonstrated a 22.10 % increase in sensitivity
for the histologic cancer (CIS/SCC/AC) category over
HPV16/18 tests alone. Comparison of the hrHPV-positive
rates obtained with the three algorithms with that of the
CIN2− group indicated a decrease in the positivity rate
obtained using algorithms 1–3 to 29.9, 34.71, and 26.46 %,
with a cancer detection rate of 95.77, 100, and 100 %,
respectively.
Because of the large population, screening programs
for cervical cancer are difficult to implement in China.
However, the incidence of cervical cancer has decreased
to a greater degree in urban areas than in rural areas be-
cause of the implementation of opportunistic screening
in hospitals. Pap smear testing has been the major tool
used for opportunistic screening in China over the past
several decades. A survey of 202,231 patients in a retro-
spective opportunistic-screening study of 12 of the 3A
hospitals in 2005 demonstrated that liquid-based cy-
tology remained the major screening method in China
[34], whereas hrHPV co-testing with cytology was uti-
lized for approximately 11.7 % of patients in the study.
Accordingly, physicians face problems in delivering accur-
ate diagnoses such as a low positive cytologic detection
rate and a high false-positive rate of hrHPV detection,
which result in insufficient treatment or over-treatment,
respectively. To address these concerns, we suggest that
combining gene testing with gross clinical history/examin-
ation findings in the outpatient departments of hospitals
would provide a first step toward reducing the incidence
of cervical cancer in China.
Conclusions
Algorithms that include molecular tests (methylated
PAX1, ZNF582, and HPV16/18) in combination with clin-
ical examination findings provide an effective method to
increase the accuracy of diagnosis for cervical cancer. In
this study, we established and validated algorithms that
Table 4 Sensitivity, specificity, and odds ratios of the three clinical risk factor algorithms for CIN3+ or CIS/SCC/AC detection
Target genes Cutoff Sensitivity (%) (95 % CI) Specificity (%) (95 % CI) AUC (%) (95 % CI) Odds ratio (95 % CI) P value
CIN3+ lesion
Algorithm 1 220 89.87 (84.18–93.67) 75.95 (70.72–80.50) 82.9 (78.9–86.9) 28.02 (15.65–50.17) <0.001
Algorithm 2 220 86.08 (79.82–90.62) 80.76 (75.84–84.87) 83.4 (79.3–87.5) 25.94 (15.17–44.36) <0.001
Algorithm 3 220 92.41 (87.19–95.60) 72.51 (67.11–77.32) 82.5 (78.5–86.4) 32.09 (16.88–61.00) <0.001
CIS/SCC/AC
Algorithm 1 220 96.51 (90.24–98.81) 64.46 (59.41–69.21) 78.8 (74.2–83.5) 50.19 (15.55–161.98) <0.001*
Algorithm 2 220 100.0 (94.87–100.0) 70.80 (65.92–75.24) 84.0 (80.4–87.6) – –
Algorithm 3 220 100.0 (94.87–100.0) 61.43 (56.33–66.30) 79.5 (75.3–83.7) – –
P value determined by chi-squared test and *Fisher’s exact test; odds ratio for CIN3+ or CIS/SCC/AC
CI confidence interval, Genem methylated gene
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could be used as an objective screening method in the
outpatient departments of hospitals to reduce the num-
bers of patients with cervical cancer. These algorithms
might lead to the establishment of accurate, objective,
non-morphological, and molecular-based test systems for
cervical diagnosis in developing countries or countries
where resources are not evenly distributed.
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histologic category in training set. (PPTX 47 kb)
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